Abbott Laboratories (ABT) Common Equity (2009 - 2026)

Abbott Laboratories' Common Equity history runs 18 years deep, the most recent figure standing at $52.7 billion for Q1 2026.

• In Q1 2026, Common Equity rose 9170.74% year-over-year to $52.7 billion; the TTM figure through Mar 2026 stood at $52.7 billion (up 9170.74% YoY), while the FY2025 annual figure was $52.1 billion, up 107.25% from the prior year.
• Common Equity came in at $52.7 billion for Q1 2026 at Abbott Laboratories, up from $52.1 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $52.7 billion in Q1 2026 to a low of -$8.7 billion in Q2 2022.
• A 5-year average of $20.0 billion and a median of $24.9 billion in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity sank 8783.67% in 2022 and jumped 30897.47% in 2023, its largest moves.
• Abbott Laboratories' Common Equity stood at $35.3 billion in 2022, then retreated by 29.46% to $24.9 billion in 2023, then increased by 1.14% to $25.2 billion in 2024, then surged by 107.25% to $52.1 billion in 2025, then increased by 1.1% to $52.7 billion in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $52.7 billion, $52.1 billion, and $51.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison